/

Empresas

Sy

No verificado

Synthekine Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

9 Comunicados de prensa

Ver todos los comunicados de prensa

26/02/2026

Mercado laboral

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer

Fuente

Synthekine Inc.

Editor

1.00

0

23/02/2026

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Mercado laboral

Synthekine Appoints Biotechnology and Pharmaceutical Industry Veteran John A. Orwin as Chair of its Board of Directors

Fuente

Synthekine Inc.

Editor

1.00

0

13/11/2025

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

First Patient Dosed in SYNERGY-101, a Global, Randomized Phase 2 Clinical Trial of STK-012 in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer

Fuente

Synthekine Inc.

Editor

1.00

0

07/11/2025

Eventos

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer

Fuente

Synthekine Inc.

Editor

1.00

0

30/10/2025

Ciencia

Biotecnología

Medicina - Varios

Sanidad

Farmacéutica

Salud

Oncología

Análisis de Mercados

Synthekine Announces Late-Breaking Oral Presentation of Initial Clinical Data of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous NSCLC at SITC 2025 Annual Meeting

Fuente

Synthekine Inc.

Editor

1.00

0

09/12/2024

Ciencia

Medicina - Varios

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

Eventos

Ferias y Congresos

Industria

Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting

Fuente

Synthekine Inc.

Editor

1.00

0

15/11/2024

Eventos

Industria

Oncología

Salud

Sanidad

Ciencia

Biotecnología

Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024

Fuente

Synthekine Inc.

Editor

1.00

0

08/11/2024

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Synthekine Announces Presentation of New Translational Data from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Fuente

Synthekine Inc.

Editor

1.00

0

04/09/2024

Industria

Ciencia

Biotecnología

Farmacéutica

Sanidad

Salud

Higiene alimentaria

Medicina - Varios

Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion

Fuente

Synthekine Inc.

Editor

1.00

0

Seguidores

0

Compatibilidad

0